



esketamine (Spravato®) Nasal Spray

INTRANASAL SPRAY FOR ADMINISTRATION UNDER SUPERVISION OF A HEALTHCARE PROFESSIONAL

PRIOR REVIEW/CERTIFICATION REQUEST FOR SERVICES FORM

INCOMPLETE FORMS MAY DELAY PROCESSING

ALL NC PROVIDERS MUST PROVIDE THEIR 5-DIGIT Blue Cross NC PROVIDER ID# BELOW

PATIENT NAME		BLUE CROSS NC MEMBER ID NUMBER	PATIENT DATE OF BIRTH
REQUESTING PROVIDER INFORMATION		SERVICING PROVIDER OR FACILITY LOCATION (for services to be performed outside of the physician office)	
Provider Name		Servicing Provider	
Provider #, Tax ID # or NPI		Facility Name	
Street, Bldg., Suite #		Servicing provider or Facility #, or NPI #	
City/State/Zip code		Street, Bldg., Suite #	
Phone #		City/State/Zip code	
Fax #			
PLACE OF SERVICE: <input type="checkbox"/> Home Infusion <input type="checkbox"/> Office <input type="checkbox"/> Outpatient hospital <input type="checkbox"/> Specialty Pharmacy			
Specialty Pharmacy:		Specialty Pharmacy NPI:	
HCPCS CODE: <input type="checkbox"/> J0013 <input type="checkbox"/> G2082 <input type="checkbox"/> G2083		CPT/Other billing code:	
Primary Diagnosis:		ICD-10:	
Drug Requested:			
Strength & Route of Administration:			

Please answer the following questions for INITIAL coverage:

See page 3 for continuation coverage; see page 5 for quantity limit exceptions

1. Will the requested medication be billed via medical benefits?..... Yes No
If NO, please complete the Spravato – NC Standard form to request pharmacy benefits.
2. Is the patient 18 years of age or older?..... Yes No
3. Has the patient been diagnosed with **treatment-resistant depression (TRD)**?..... Yes No
If YES, please answer the following questions:
 - a. Does the patient have a confirmed diagnosis of major depressive disorder (MDD)?.... Yes No
If YES, please answer the following questions:
 - i. Does the patient have a diagnosis of single-episode MDD?..... Yes No
 1. **If YES**, has the duration been ≥ 2 years?..... Yes No
 - ii. Does the patient have recurrent MDD without psychotic features?..... Yes No
 - b. In the current depressive episode, has the patient had an inadequate response (≤ 25% improvement) to at least two different oral antidepressants, from at least two different classes (e.g., SSRIs, SNRIs, TCAs, bupropion, mirtazapine, etc.), of adequate dose and duration (typically 6 weeks)?..... Yes No

****continued on page 2; please complete and sign page 2 for prior authorization request****

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the priority of their respective owners.

esketamine (Spravato®) Nasal Spray - continued

- 4. Has the patient been diagnosed with **major depressive disorder (MDD)** with suicidal ideation or behavior?..... Yes No
If YES, please answer the following questions:
 - a. Is the suicidal ideation and intent imminent and warrant potential hospitalization?..... Yes No
 - b. Will the patient receive this medication in conjunction with an oral antidepressant medication?..... Yes No
- 5. At initiation of esketamine nasal spray therapy, does/did the patient have a depression symptom severity of ≥ 28 on the Montgomery-Asberg Depression Rating Scale (MADRS), or as scored by a comparable standardized rating scale that reliably measures depressive symptoms?..... Yes No
- 6. Will the patient receive esketamine nasal spray in combination with ketamine, of any formulation or route of administration, for the same indication?..... Yes No
- 7. Does the patient have any clinical contraindications to esketamine nasal spray therapy (i.e., aneurysmal vascular disease or intracerebral hemorrhage)?..... Yes No
- 8. Is the prescriber a specialist in the area of the patient’s diagnosis (i.e., psychiatrist)?..... Yes No
- 9. Will the requested medication be administered under direct supervision of a healthcare professional at a treatment facility that is certified through the Spravato (esketamine) REMS program?..... Yes No
 - a. **IF YES**, will the requested medication be administered to the individual patient for whom it has been specifically prescribed and ordered, and within 14 days after receipt by the REMS-certified treatment facility?..... Yes No
- 10. Is the requested quantity within the maximum units allowed (see table on page 6)?..... Yes No
If NO, please complete page 5 for a quantity limit exception.

Please certify the following by signing and dating below:

I certify that I have been authorized to request prior review and certification for the above requested service(s). I further certify that my patient’s medical records accurately reflect the information provided. I understand that Blue Cross NC may request medical records for this patient at any time in order to verify this information. I further understand that if Blue Cross NC determines this information is not reflected in my patient’s medical records, Blue Cross NC may request a refund of any payments made and/or pursue any other remedies available.

Prescriber’s Signature (Required):_____ **Date:**_____

For Blue Cross NC members, fax form to 1-888-348-7332



esketamine (Spravato®) Nasal Spray - CONTINUATION

**INTRANASAL SPRAY FOR ADMINISTRATION UNDER SUPERVISION OF A HEALTHCARE PROFESSIONAL
PRIOR REVIEW/CERTIFICATION REQUEST FOR SERVICES FORM**

INCOMPLETE FORMS MAY DELAY PROCESSING

ALL NC PROVIDERS MUST PROVIDE THEIR 5-DIGIT Blue Cross NC PROVIDER ID# BELOW

PATIENT NAME		BLUE CROSS NC MEMBER ID NUMBER	PATIENT DATE OF BIRTH
REQUESTING PROVIDER INFORMATION		SERVICING PROVIDER OR FACILITY LOCATION (for services to be performed outside of the physician office)	
Provider Name		Servicing Provider	
Provider #, Tax ID # or NPI		Facility Name	
Street, Bldg., Suite #		Servicing provider or Facility #, or NPI #	
City/State/Zip code		Street, Bldg., Suite #	
Phone #		City/State/Zip code	
Fax #			
PLACE OF SERVICE: <input type="checkbox"/> Home Infusion <input type="checkbox"/> Office <input type="checkbox"/> Outpatient hospital <input type="checkbox"/> Specialty Pharmacy			
Specialty Pharmacy:		Specialty Pharmacy NPI:	
HCPCS CODE: <input type="checkbox"/> J0013 <input type="checkbox"/> G2082 <input type="checkbox"/> G2083		CPT/Other billing code:	
Primary Diagnosis:		ICD-10:	

Please answer the following questions for CONTINUATION coverage:

1. Was the patient approved for initial coverage for the requested medication through Blue Cross NC?..... Yes No
If NO, please answer all questions on pages 1-2. If YES, please answer the following questions:
2. Will the requested medication be billed via medical benefits?..... Yes No
If NO, please complete the Spravato – NC Standard form to request pharmacy benefits.
3. Does the patient have a diagnosis of **treatment-resistant depression (TRD)**?..... Yes No
4. Does the patient have a diagnosis of **major depressive disorder (MDD)** with suicidal ideation or behavior?..... Yes No
 - a. **If YES**, will the patient continue therapy with an oral antidepressant agent in conjunction with the requested medication?..... Yes No
5. Using the MADRS scale or a comparable standardized rating scale that reliably measures depressive symptoms, has the patient demonstrated at least a 50% reduction in depressive symptoms compared to baseline while on esketamine nasal spray therapy?..... Yes No
6. Will the patient receive esketamine nasal spray in combination with ketamine, of any formulation or route of administration, for the same indication?..... Yes No
7. Does the patient have any clinical contraindications to esketamine therapy (i.e., aneurysmal vascular disease or intracerebral hemorrhage)?..... Yes No
8. Is this medication prescribed by or in consultation with a psychiatrist?..... Yes No
9. Will the requested medication be administered under direct supervision of a healthcare professional at a treatment facility that is certified through the Spravato (esketamine) REMS program?..... Yes No
 - a. **If YES**, will the requested medication be administered to the individual patient for whom it has been specifically prescribed and ordered, and within 14 days after receipt by the REMS-certified treatment facility?..... Yes No
10. Is the requested quantity within the maximum units allowed (see table on page 6)?..... Yes No
If NO, please complete page 5 for a quantity limit exception.

*****continued on page 4; please complete and sign page 4 for prior authorization request*****

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners.



esketamine (Spravato[®]) Nasal Spray - *continued*

Please certify the following by signing and dating below:

I certify that I have been authorized to request prior review and certification for the above requested service(s). I further certify that my patient's medical records accurately reflect the information provided. I understand that Blue Cross NC may request medical records for this patient at any time in order to verify this information. I further understand that if Blue Cross NC determines this information is not reflected in my patient's medical records, Blue Cross NC may request a refund of any payments made and/or pursue any other remedies available.

Prescriber's Signature (Required): _____ **Date:** _____

For Blue Cross NC members, fax form to 1-888-348-7332



esketamine (Spravato®) Nasal Spray - QUANTITY LIMIT EXCEPTION

INTRANASAL SPRAY FOR ADMINISTRATION UNDER SUPERVISION OF A HEALTHCARE PROFESSIONAL

PATIENT NAME		BLUE CROSS NC MEMBER ID NUMBER		PATIENT DATE OF BIRTH	
REQUESTING PROVIDER INFORMATION			SERVICING PROVIDER OR FACILITY LOCATION (for services to be performed outside of the physician office)		
Provider Name		Servicing Provider			
Provider #, Tax ID # or NPI		Facility Name			
Street, Bldg., Suite #		Servicing provider or Facility #, or NPI #			
City/State/Zip code		Street, Bldg., Suite #			
Phone #		City/State/Zip code			
Fax #					
PLACE OF SERVICE: <input type="checkbox"/> Home Infusion <input type="checkbox"/> Office <input type="checkbox"/> Outpatient hospital <input type="checkbox"/> Specialty Pharmacy					
Specialty Pharmacy:			Specialty Pharmacy NPI:		
HCPCS CODE: <input type="checkbox"/> J0013 <input type="checkbox"/> G2082 <input type="checkbox"/> G2083			CPT/Other billing code:		
Primary Diagnosis:			ICD-10:		
Drug Requested:					
Strength & Route of Administration:					

FOR COVERAGE OVER THE FDA LABELED DOSING (SEE TABLE ON PAGE 6), PLEASE ANSWER THE FOLLOWING:

Please note: This medication requires a prior authorization before a quantity limit override can be considered. Before submitting a request for a quantity level override, please ensure that a prior approval authorization has been submitted and/or approved (pages 1-2 or page 3-4). Otherwise, this request will deny.

Requested units: _____
 Please enter quantity as a numeric value with one decimal place (ex. 1.0, 1.5)*

In the space provided, please document support for the requested Quantity Limit Exception (this may include documented clinical rationale and/or medical records).

Please certify the following by signing and dating below:
 I certify that I have been authorized to request prior review and certification for the above requested service(s). I further certify that my patient’s medical records accurately reflect the information provided. I understand that Blue Cross NC may request medical records for this patient at any time in order to verify this information. I further understand that if Blue Cross NC determines this information is not reflected in my patient’s medical records, Blue Cross NC may request a refund of any payments made and/or pursue any other remedies available.
Prescriber’s Signature (Required): _____ **Date:** _____

For Blue Cross NC members, fax form to 1-888-348-7332

esketamine (Spravato®) Nasal Spray - QUANTITY LIMITS

INTRANASAL SPRAY FOR ADMINISTRATION UNDER SUPERVISION OF A HEALTHCARE PROFESSIONAL

FDA Label Reference				
Medication	Indication	Dosing [^]	HCPCS	Maximum Units*
esketamine (Spravato®) nasal spray	Treatment Resistant Depression (TRD)	<p>Induction (Weeks 1-4): Administer twice weekly starting Day 1 with 56mg dose, may increase to 84mg subsequently</p> <p>Maintenance (Weeks 5-8): Administer once weekly (56mg or 84mg)</p> <p>Maintenance (Weeks 9 and after): Administer every 2 weeks or once weekly (56mg or 84mg) Dosing frequency should be individualized to the least frequent dosing to maintain remission/response.</p> <p>Note: Evidence of therapeutic benefit should be evaluated at the end of the 4-week induction phase to determine need for continued treatment.</p>	<p>J0013</p> <p>G2082**</p> <p>G2083**</p>	<p>Initial: 2,016</p> <p>Continuation: 4,032</p>
	Depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior	<p>84 mg twice per week for 4 weeks, may be reduced to 56mg twice per week based on tolerability</p> <p>Note: Evidence of therapeutic benefit should be evaluated after 4 weeks to determine need for continued treatment. Treatment beyond 4 weeks has not been systematically evaluated.</p>		

*Maximum units allowed for duration of approval

**Please note the following applicable HCPCS codes:

- G2082 – Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified healthcare professional and provision of up to 56 mg of esketamine nasal self-administration, includes 2 hours post-administration observation
- G2083 – Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified healthcare professional and provision of greater than 56 mg of esketamine nasal self-administration, includes 2 hours post-administration observation
- For requests where the drug is supplied/dispensed AND administered with monitoring at the same site, only G codes combining both the drug and service should be submitted (i.e., G2082 or G2083)
- For requests where the drug is supplied/dispensed by a different site (e.g., specialty pharmacy) than where the drug is administered with monitoring (e.g., physician office), separate codes for the drug and service should be submitted (i.e., J0013 and the most appropriate E/M CPT code for the service)